Abstract

Cytochrome P450 2D6 (CYP2D6) metabolizes a wide range of therapeutic drugs. CYP2D6 substrates typically contain a basic nitrogen atom, and the active-site residue Asp-301 has been implicated in substrate recognition through electrostatic interactions. Our recent computational models point to a predominantly structural role for Asp-301 in loop positioning (Kirton, S. B., Kemp, C. A., Tomkinson, N. P., St.-Gallay, S., and Sutcliffe, M. J. (2002) Proteins 49, 216-231) and suggest a second acidic residue, Glu-216, as a key determinant in the binding of basic substrates. We have evaluated the role of Glu-216 in substrate recognition, along with Asp-301, by site-directed mutagenesis. Reversal of the Glu-216 charge to Lys or substitution with neutral residues (Gln, Phe, or Leu) greatly decreased the affinity (K(m) values increased 10-100-fold) for the classical basic nitrogen-containing substrates bufuralol and dextromethorphan. Altered binding was also manifested in significant differences in regiospecificity with respect to dextromethorphan, producing enzymes with no preference for N-demethylation versus O-demethylation (E216K and E216F). Neutralization of Asp-301 to Gln and Asn had similarly profound effects on substrate binding and regioselectivity. Intriguingly, removal of the negative charge from either 216 or 301 produced enzymes (E216A, E216K, and D301Q) with elevated levels (50-75-fold) of catalytic activity toward diclofenac, a carboxylate-containing CYP2C9 substrate that lacks a basic nitrogen atom. Activity was increased still further (>1000-fold) upon neutralization of both residues (E216Q/D301Q). The kinetic parameters for diclofenac (K(m) 108 microm, k(cat) 5 min(-1)) along with nifedipine (K(m) 28 microm, k(cat) 2 min(-1)) and tolbutamide (K(m) 315 microm, k(cat) 1 min(-1)), which are not normally substrates for CYP2D6, were within an order of magnitude of those observed with CYP3A4 or CYP2C9. Neutralizing both Glu-216 and Asp-301 thus effectively alters substrate recognition illustrating the central role of the negative charges provided by both residues in defining the specificity of CYP2D6 toward substrates containing a basic nitrogen.

Highlights

  • Cytochrome P450 2D6 (CYP2D6) metabolizes a wide range of therapeutic drugs

  • A number of structural models have pointed to aspartate 301 in the I helix being the specific residue involved (4, 16 –18). This is supported by mutagenesis studies that showed that substitution of Asp-301 by neutral residues leads to a marked reduction in catalytic activity against “classical” CYP2D6 substrates [17, 19, 20], it has little effect on activity against a substrate lacking a basic nitrogen [10]

  • We report site directed mutagenesis studies of Glu-216 and Asp-301 aimed at clarifying their respective roles in CYP2D6 substrate specificity and regiospecificity

Read more

Summary

Introduction

Cytochrome P450 2D6 (CYP2D6) metabolizes a wide range of therapeutic drugs. CYP2D6 substrates typically contain a basic nitrogen atom, and the active-site residue Asp-301 has been implicated in substrate recognition through electrostatic interactions. The kinetic parameters for diclofenac (Km 108 ␮M, kcat 5 min؊1) along with nifedipine (Km 28 ␮M, kcat 2 min؊1) and tolbutamide (Km 315 ␮M, kcat 1 min؊1), which are not normally substrates for CYP2D6, were within an order of magnitude of those observed with CYP3A4 or CYP2C9 Neutralizing both Glu-216 and Asp-301 effectively alters substrate recognition illustrating the central role of the negative charges provided by both residues in defining the specificity of CYP2D6 toward substrates containing a basic nitrogen. A number of structural models have pointed to aspartate 301 in the I helix being the specific residue involved (4, 16 –18) (see Fig. 1) This is supported by mutagenesis studies that showed that substitution of Asp-301 by neutral residues leads to a marked reduction in catalytic activity against “classical” CYP2D6 substrates [17, 19, 20], it has little effect on activity against a substrate lacking a basic nitrogen [10]. Library-efficient competent Escherichia coli JM109 were purchased from Promega

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call